Home › Trial NCT03207555
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
- Trial IDNCT03207555
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorM.D. Anderson Cancer Center
- Enrollment23
- Start date2018-05-23
- ConditionsMalignant Neoplasms Stated as Primary Lymphoid Haematopoietic · Chronic Lymphocytic Leukemia · Small Lymphocytic Leukemia
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.